Objective: To evaluate the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on alcohol-related outcomes in adults with or without alcohol use disorder (AUD).Methods: A systematic review and meta-analysis following PRISMA guidelines searched PubMed, Embase, and Cochrane Library up to May 3, 2025. Eligible studies included randomized controlled trials (RCTs) and observational studies assessing GLP-1RAs (e.g.,… Continue reading The effects of glucagon-like peptide-1 receptor agonists (#GLP1-RAs ) on #alcohol -related outcomes: a systematic review and meta-analysis
Tag: GLP-1
#Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related #Macular #Degeneration
Importance Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are extensively used in treating diabetes and obesity, yet little is known about the long-term ocular effects of systemic prolonged exposure.Objective To evaluate the risk of developing neovascular age-related macular degeneration (nAMD) associated with the use of GLP-1 RAs in patients with diabetes.Design, Setting, and Participants This population-based,… Continue reading #Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related #Macular #Degeneration
GLP-1RA and SGLT2i Medications for Type 2 #Diabetes and #Alzheimer Disease and Related Dementias
Importance The association between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) and risk of Alzheimer disease and related dementias (ADRD) remains to be confirmed.Objective To assess the risk of ADRD associated with GLP-1RAs and SGLT2is in people with type 2 diabetes (T2D).Design, Setting, and Participants This target trial emulation study used electronic… Continue reading GLP-1RA and SGLT2i Medications for Type 2 #Diabetes and #Alzheimer Disease and Related Dementias
Glucagon-Like Peptide-1 Receptor Agonists and Risk for #Depression in Older Adults With Type 2 #Diabetes
Background:Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown potential antidepressant effects, population studies yield inconsistent results. Objective:To compare the risk for depression in older adults with type 2 diabetes (T2D) initiating treatment with GLP-1RAs versus sodium–glucose cotransporter-2 inhibitors (SGLT2is) or dipeptidyl peptidase-4 inhibitors (DPP4is).Design:Target trial emulation study.Setting:U.S. National Medicare administrative data from January 2014 to… Continue reading Glucagon-Like Peptide-1 Receptor Agonists and Risk for #Depression in Older Adults With Type 2 #Diabetes
Age and Sex Differences in Efficacy of Treatments for Type 2 #DiabetesA Network Meta-Analysis
Question Does the efficacy of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase 4 inhibitors vary by age and sex among individuals with type 2 diabetes?Findings In this systematic review and network meta-analysis of 601 eligible trials (including 103 trials with individual participant data), there was a greater reduction in the risk… Continue reading Age and Sex Differences in Efficacy of Treatments for Type 2 #DiabetesA Network Meta-Analysis
#GLP-1 programs the neurovascular landscape
Readily available nutrient-rich foods exploit our inherent drive to overconsume, creating an environment of overnutrition. This transformative setting has led to persistent health issues, such as obesity and metabolic syndrome. The development of glucagon-like peptide-1 receptor (GLP-1R) agonists reveals our ability to pharmacologically manage weight and address metabolic conditions. Obesity is directly linked to chronic… Continue reading #GLP-1 programs the neurovascular landscape
Quantified Metrics of #Gastric Emptying Delay by #Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management
INTRODUCTION: Divergent recommendations for periprocedural management of glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 RA) medications rely on limited evidence. We performed a systematic review and meta-analysis to provide quantitative measures of gastric emptying relevant to mechanisms of weight loss and to periprocedural management of GLP-1 RA. We hypothesized that the magnitude of gastric emptying delay would… Continue reading Quantified Metrics of #Gastric Emptying Delay by #Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management
#Glucagon-like peptide-1 receptor agonists and #stroke: A systematic review and meta-analysis of #cardiovascular outcome trials
Background:In patients surviving stroke, approximately 15% and 60% exhibit concurrent diabetes mellitus and overweight/obesity, respectively, necessitating heightened secondary prevention efforts. Despite glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrating improved outcomes for those with diabetes mellitus or obesity, their underutilization persists among eligible individuals. This systematic review and meta-analysis investigated the impact of GLP-1 RAs on… Continue reading #Glucagon-like peptide-1 receptor agonists and #stroke: A systematic review and meta-analysis of #cardiovascular outcome trials
2 Medical News 